---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005641"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:27:28.110417+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PowerUp shareholders approve merger with Aspire Biopharma; redemptions of ~$5.8M

## Summary
- All proposals approved at Feb 4 meeting, including business combination, domestication, and charter changes.
- 507,631 shares redeemed for $5.8M ($11.43/share), leaving ~$5.8M removed from trust.
- Closing expected before Feb 17, 2025; combined company to trade as ASBP (common) and ASBPW (warrants) on Nasdaq.
- Seven directors elected to staggered board, including Kraig Higginson, Michael Howe, Gary Stein, others.
- Adjournment proposal not needed due to sufficient votes for all proposals.

## SEC filing metadata
- accession: 0001493152-25-005641
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315225005641/0001493152-25-005641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315225005641/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005641
- JSON: https://secwatch.observer/filing/0001493152-25-005641.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.